– Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI –
NeuroTrauma Sciences, LLC (NTS), a private biopharmaceutical company developing a portfolio of disease-modifying therapeutic candidates to treat the devastating effects of acquired brain injury, today announced that it has awarded a grant to Jonathan Lifshitz, PhD, professor at the University of Arizona College of Medicine – Phoenix who leads the Neurotrauma & Social Impact research team, to conduct preclinical research on its novel neuroprotective compound NTS-104 in mild traumatic brain injury (mTBI), with a focus on addressing clinically-relevant outcome measures such as anxiety, depression, cognitive dysfunction, and sleep-wake disturbances.